New therapy for bone regeneration

José Antonio Rodríguez (third from the right) with researchers from the CIMA Cardiovascular Disease Program who have participated in the work. / Manuel Castells

Spanish researchers have developed a strategy based on biomaterials and therapeutic proteins to regenerate bones. The results, published in Drug Delivery, have been tested in experimental models in order to enhance the reparative response of bone morphogenetic protein 2 and increase the rate of bone mineralization.

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra and the Biomedical Research Center of the Canary Islands, attached to the University of La Laguna, have developed a new strategy based on biomaterials and therapeutic proteins that regenerates bone for cases with large losses of bone mass.
The recombinant human BMP2 protein is capable of stimulating bone production; currently used in orthopedic surgery and trauma in the US.

The work demonstrates that metalloproteinase 10 (MMP10) accelerates the regeneration of bone in experimental models, by enhancing the reparative response of the bone morphogenetic protein 2 (BMP-2) and increasing the rate of bone mineralization. The results have been published in Drug Delivery.

The human recombinant BMP2 protein is capable of stimulating the production of bone, so that it is currently used in orthopedic surgery and traumatology in the United States. In addition, it is also used in the field of oral surgery and dentistry, for the repair of bone defects and as a treatment prior to the placement of dental implants.

“However, its possible side effects restrict its application to very specific defects. Therefore, the design of new bioactive systems that enhance its osteogenic effect and reduce the required doses would allow a more rational and safe use of this protein “, explains José Antonio Rodríguez, researcher of the CIMA Cardiovascular Disease Program and member of the Research Center Biomedical in Cardiovascular Network (CIBERCV).

Rodríguez is the coordinator of the work, along with Carmen Évora and Araceli Delgado, from the Pharmaceutical Technology Laboratory of the University of La Laguna. According to the researchers of the work, the proposal of the joint administration of BMP-2 and MMP10 can constitute a strategy with clinical application, particularly effective for the regeneration and repair of bone defects.

Bibliographic reference:
Drug Deliv 2018 Vol 25(1):750-756. doi: 10.1080/10717544.2018.1446473

Sources: SINC and CIMA of the University of Navarra